Lisata Q2 net loss $4.7M, cash $22M; certepetide trials advancing with multiple data milestones ahead

LISATA THERAPEUTICS, INC.

2025-Q2 EPS reported -$1.09 revenue$70,000

Net loss of $4.7M vs $5.0M in Q2 2024; revenue of $70K from Catalent license fee.
Cash, equivalents and securities total $22.0M; runway into Q4 2026 funds all active trials to next data milestone.
ASCEND Phase 2b Cohort B showed positive PFS and ORR signal; final data expected late 2025.
BOLSTER Phase 2a first-line CCA enrollment complete; topline data due Q4 2025.
USPTO issued new composition-of-matter patent for certepetide (U.S. 12,351,653) extending protection to March 2040.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.